A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States
Recruiting - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States
Recruiting - Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States
Recruiting - Memorial Sloan Kettering Suffolk - Commack
Commack, New York, United States
Recruiting - Memorial Sloan Kettering Westchester
Harrison, New York, United States
Recruiting - Memorial Sloan Kettering Cancer Center
New York, New York, United States
Recruiting - Memorial Sloan Kettering Nassau (limited Protocol Activities)
Uniondale, New York, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Jan 2023
- Primary completion
- 31 Jan 2027
- Completion
- 31 Jan 2027
- Last update posted
- 18 Nov 2025
- Registered enrollment
- 18
- Registry id
- NCT05714072
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.